Corey Davis
Stock Analyst at HC Wainwright & Co.
(2.47)
# 2,341
Out of 4,905 analysts
17
Total ratings
64.29%
Success rate
9.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corey Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Reiterates: Neutral | $480 → $390 | $24.94 | +1,463.75% | 5 | May 12, 2020 | |
| SCYX SCYNEXIS | Assumes: Buy | $50 | $0.73 | +6,796.55% | 3 | May 7, 2018 | |
| VTVT vTv Therapeutics | Downgrades: Neutral | $560 → $40 | $16.49 | +142.57% | 2 | Apr 10, 2018 | |
| LPCN Lipocine | Initiates: Buy | $170 | $3.12 | +5,356.59% | 1 | Mar 29, 2018 | |
| VNDA Vanda Pharmaceuticals | Initiates: Buy | $20 | $4.78 | +318.41% | 2 | Jan 19, 2018 | |
| PCRX Pacira BioSciences | Initiates: Buy | $50 | $21.59 | +131.64% | 3 | Jan 19, 2018 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Neutral | $144 | $112.87 | +27.58% | 1 | Aug 25, 2017 |
Nektar Therapeutics
May 12, 2020
Reiterates: Neutral
Price Target: $480 → $390
Current: $24.94
Upside: +1,463.75%
SCYNEXIS
May 7, 2018
Assumes: Buy
Price Target: $50
Current: $0.73
Upside: +6,796.55%
vTv Therapeutics
Apr 10, 2018
Downgrades: Neutral
Price Target: $560 → $40
Current: $16.49
Upside: +142.57%
Lipocine
Mar 29, 2018
Initiates: Buy
Price Target: $170
Current: $3.12
Upside: +5,356.59%
Vanda Pharmaceuticals
Jan 19, 2018
Initiates: Buy
Price Target: $20
Current: $4.78
Upside: +318.41%
Pacira BioSciences
Jan 19, 2018
Initiates: Buy
Price Target: $50
Current: $21.59
Upside: +131.64%
Jazz Pharmaceuticals
Aug 25, 2017
Initiates: Neutral
Price Target: $144
Current: $112.87
Upside: +27.58%